Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001171843-26-001299
- form_type
- 8-K
- ticker
- ABUS
- cik
- 0001447028
- company_name
- Arbutus Biopharma Corp
- filed_at
- 2026-03-03T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:35.104101+00:00
- generated_at
- 2026-05-15T22:12:50.989650+00:00
- sec_items
- ["1.01", "8.01", "9.01"]
- event_type
- litigation
- sentiment
- positive
- materiality_score
- 0.9
- calibrated_materiality_score
- 0.9
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001171843-26-001299
- json_url
- https://secwatch.observer/filing/0001171843-26-001299.json
- markdown_url
- https://secwatch.observer/filing/0001171843-26-001299.md
- text_url
- https://secwatch.observer/filing/0001171843-26-001299.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1447028/000117184326001299/0001171843-26-001299-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1447028/000117184326001299/f8k_030326.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
AGAE
Allied Gaming settles litigation with Knighted for ~$5.94M paid over 3 months; CEO Li personally guarantees payment
Allied Gaming & Entertainment Inc.
April 21, 2026, 7:59 PM ET
litigation
Items 1.01, 5.02, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 8.01, 9.01
same event type: litigation
similar materiality
This filing
On March 3, 2026 (the “Effective Date”), Arbutus Biopharma Corporation (“Arbutus” or the “Company”), Genevant Sciences GmbH (“Genevant” and together with Arbutus, “Arbutus/Genevant”), and, solely for certain purposes, Genevant Sciences Ltd., and Moderna, Inc. and ModernaTx, Inc. (together, “Moderna”) entered into a settlement agreement (the “Settlement Agreement”) to resolve all patent infringement litigation between Arbutus/Genevant and Moderna pending in the U.S. and internationally relating to Moderna’s unauthorized use of Arbutus/Genevant’s lipid nanoparticle (“LNP”) delivery technology in its vaccines, including Spikevax® (the “LNP Litigation”).
Comparable filing
On April 10, 2026, Allied Gaming & Entertainment Inc. (the “Company”) and Yangyang Li, its Chief Executive Officer and Chairman, in his personal capacity (“Mr. Li”, and together with the Company, the “Allied Parties”) entered into a binding Term Sheet for Global Resolution (the “Term Sheet”) with Knighted Pastures, LLC (“Knighted”) and Roy Choi, in his personal capacity (“Mr. Choi”, and together with Knighted, the “Knighted Parties”).
Filing page
SEC filing
TRNR
TRNR recovers $6.4M in full settlement of Sportstech loan dispute, ends legal proceedings
Interactive Strength, Inc.
March 5, 2026, 6:59 PM ET
litigation
Items 1.01, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 8.01, 9.01
same event type: litigation
similar materiality
This filing
On March 3, 2026 (the “Effective Date”), Arbutus Biopharma Corporation (“Arbutus” or the “Company”), Genevant Sciences GmbH (“Genevant” and together with Arbutus, “Arbutus/Genevant”), and, solely for certain purposes, Genevant Sciences Ltd., and Moderna, Inc. and ModernaTx, Inc. (together, “Moderna”) entered into a settlement agreement (the “Settlement Agreement”) to resolve all patent infringement litigation between Arbutus/Genevant and Moderna pending in the U.S. and internationally relating to Moderna’s unauthorized use of Arbutus/Genevant’s lipid nanoparticle (“LNP”) delivery technology in its vaccines, including Spikevax® (the “LNP Litigation”).
Comparable filing
On February 27, 2026, the Company and Sportstech entered into a Settlement Agreement (the “Settlement Agreement”), pursuant to which Sportstech was to pay the Company $6,350,000 along with making a payment to the Company’s counsel in its legal dispute with Sportstech (the “Settlement Payment”).
Filing page
SEC filing
ROIV
Roivant's Genevant/Arbutus settles Moderna LNP patent suit for $950M upfront, plus $1.3B contingent
Roivant Sciences Ltd.
March 3, 2026, 6:59 PM ET
litigation
Items 1.01, 7.01, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 8.01, 9.01
same event type: litigation
similar materiality
This filing
On March 3, 2026 (the “Effective Date”), Arbutus Biopharma Corporation (“Arbutus” or the “Company”), Genevant Sciences GmbH (“Genevant” and together with Arbutus, “Arbutus/Genevant”), and, solely for certain purposes, Genevant Sciences Ltd., and Moderna, Inc. and ModernaTx, Inc. (together, “Moderna”) entered into a settlement agreement (the “Settlement Agreement”) to resolve all patent infringement litigation between Arbutus/Genevant and Moderna pending in the U.S. and internationally relating to Moderna’s unauthorized use of Arbutus/Genevant’s lipid nanoparticle (“LNP”) delivery technology in its vaccines, including Spikevax® (the “LNP Litigation”).
Comparable filing
On March 3, 2026 (the “Effective Date”), Genevant Sciences GmbH (“Genevant”), a subsidiary of Roivant Sciences Ltd. (the “Company” or “Roivant”), Arbutus Biopharma Corp. (together with Genevant, “Genevant/Arbutus”), and, solely for certain purposes, Genevant Sciences Ltd., and Moderna, Inc. and ModernaTx, Inc. (together, “Moderna”) entered into a settlement agreement (the “Settlement Agreement”)
Filing page
SEC filing
OPY
Oppenheimer settles cash-sweep class action for $70M, to impact Q1 earnings
OPPENHEIMER HOLDINGS INC
April 27, 2026, 7:59 PM ET
litigation
Items 1.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: litigation
similar materiality
This filing
On March 3, 2026 (the “Effective Date”), Arbutus Biopharma Corporation (“Arbutus” or the “Company”), Genevant Sciences GmbH (“Genevant” and together with Arbutus, “Arbutus/Genevant”), and, solely for certain purposes, Genevant Sciences Ltd., and Moderna, Inc. and ModernaTx, Inc. (together, “Moderna”) entered into a settlement agreement (the “Settlement Agreement”) to resolve all patent infringement litigation between Arbutus/Genevant and Moderna pending in the U.S. and internationally relating to Moderna’s unauthorized use of Arbutus/Genevant’s lipid nanoparticle (“LNP”) delivery technology in its vaccines, including Spikevax® (the “LNP Litigation”).
Comparable filing
On April 24, 2026, Oppenheimer & Co., Inc. (“Oppenheimer”), the principal operating subsidiary of Oppenheimer Holdings Inc. (the “Company”), reached an agreement to settle the previously disclosed litigation styled Liberty Capital Group, Individually and on Behalf of All Others Similarly Situated v. Oppenheimer Holdings Inc., Oppenheimer & Co. Inc., and Oppenheimer Asset Management Inc. , No. 1:25-cv04822-JSR which was filed in the United States District Court for the Southern District of New York in June of 2025 (the “ District Court”).
Filing page
SEC filing
MRNA
Moderna settles all patent litigation with Arbutus/Genevant for $950M upfront, up to $1.3B contingent
Moderna, Inc.
March 5, 2026, 6:59 PM ET
litigation
Items 1.01
same fact type: material_agreement
same SEC item: 1.01
same event type: litigation
similar materiality
This filing
On March 3, 2026 (the “Effective Date”), Arbutus Biopharma Corporation (“Arbutus” or the “Company”), Genevant Sciences GmbH (“Genevant” and together with Arbutus, “Arbutus/Genevant”), and, solely for certain purposes, Genevant Sciences Ltd., and Moderna, Inc. and ModernaTx, Inc. (together, “Moderna”) entered into a settlement agreement (the “Settlement Agreement”) to resolve all patent infringement litigation between Arbutus/Genevant and Moderna pending in the U.S. and internationally relating to Moderna’s unauthorized use of Arbutus/Genevant’s lipid nanoparticle (“LNP”) delivery technology in its vaccines, including Spikevax® (the “LNP Litigation”).
Comparable filing
On March 3, 2026 (the “Effective Date”), Moderna, Inc. (the “Company”) and ModernaTX, Inc. (together with the Company, “Moderna”) and Arbutus Biopharma Corporation (“Arbutus”), Genevant Sciences GmbH (“Genevant” and, together with Arbutus, “Arbutus/Genevant”), and, solely for certain purposes, Genevant Sciences Ltd., entered into a settlement agreement (the “Settlement Agreement”) to resolve all patent infringement litigation between Moderna and Arbutus/Genevant pending in the U.S. and internationally (the “Litigation”).
Filing page
SEC filing
OESX
Orion settles Voltrek earnout dispute for $3M cash; solar PPA exit adds $1.3M offset
ORION ENERGY SYSTEMS, INC.
March 20, 2026, 7:59 PM ET
litigation
Items 1.01, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 8.01, 9.01
same event type: litigation
This filing
On March 3, 2026 (the “Effective Date”), Arbutus Biopharma Corporation (“Arbutus” or the “Company”), Genevant Sciences GmbH (“Genevant” and together with Arbutus, “Arbutus/Genevant”), and, solely for certain purposes, Genevant Sciences Ltd., and Moderna, Inc. and ModernaTx, Inc. (together, “Moderna”) entered into a settlement agreement (the “Settlement Agreement”) to resolve all patent infringement litigation between Arbutus/Genevant and Moderna pending in the U.S. and internationally relating to Moderna’s unauthorized use of Arbutus/Genevant’s lipid nanoparticle (“LNP”) delivery technology in its vaccines, including Spikevax® (the “LNP Litigation”).
Comparable filing
On March 17, 2026, Orion Energy Systems, Inc. and its subsidiaries (collectively, the “ Company ”) entered into a settlement agreement (the “ Settlement Agreement ”) with Final Frontier, LLC (“ Final Frontier ”) and Kathleen M. Connors (“ Ms. Connors ”), personally and as Trustee of the Kathleen M. Connors 2019 Revocable Trust
Filing page
SEC filing
SGRP
SPAR Group settles arbitration with founder Robert Brown; extends CIC agreement to 2028
SPAR Group, Inc.
May 5, 2026, 7:59 PM ET
litigation
Items 1.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: litigation
This filing
On March 3, 2026 (the “Effective Date”), Arbutus Biopharma Corporation (“Arbutus” or the “Company”), Genevant Sciences GmbH (“Genevant” and together with Arbutus, “Arbutus/Genevant”), and, solely for certain purposes, Genevant Sciences Ltd., and Moderna, Inc. and ModernaTx, Inc. (together, “Moderna”) entered into a settlement agreement (the “Settlement Agreement”) to resolve all patent infringement litigation between Arbutus/Genevant and Moderna pending in the U.S. and internationally relating to Moderna’s unauthorized use of Arbutus/Genevant’s lipid nanoparticle (“LNP”) delivery technology in its vaccines, including Spikevax® (the “LNP Litigation”).
Comparable filing
On May 1, 2026, the Company entered into a Settlement Agreement and Release with Robert G. Brown and SPAR Business Services, Inc. allowing for a dismissal of the Arbitration action between the Company and Robert G. Brown.
Filing page
SEC filing
MKTW
MarketWise settles arbitration with former CEO for $12.16M cash, redeems 520,867 units, terminates TRA rights
MARKETWISE, INC.
April 24, 2026, 7:59 PM ET
litigation
Items 1.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: litigation
This filing
On March 3, 2026 (the “Effective Date”), Arbutus Biopharma Corporation (“Arbutus” or the “Company”), Genevant Sciences GmbH (“Genevant” and together with Arbutus, “Arbutus/Genevant”), and, solely for certain purposes, Genevant Sciences Ltd., and Moderna, Inc. and ModernaTx, Inc. (together, “Moderna”) entered into a settlement agreement (the “Settlement Agreement”) to resolve all patent infringement litigation between Arbutus/Genevant and Moderna pending in the U.S. and internationally relating to Moderna’s unauthorized use of Arbutus/Genevant’s lipid nanoparticle (“LNP”) delivery technology in its vaccines, including Spikevax® (the “LNP Litigation”).
Comparable filing
On April 21, 2026, Marketwise, Inc. (the “Company”) and its subsidiary, MarketWise, LLC (together with the Company, “MarketWise”), entered into a Settlement Agreement and Release (the “Settlement Agreement”) with Mark P. Arnold, the Company’s former Chief Executive Officer, and JAMA 2021, LLC (together with Mr. Arnold, the “Arnold Parties”).
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.